What are the manufacturers of Mobosetinib/Mobosetinib?

Mobocertinib/Mobocertinib is an important targeted drug for non-small cell lung cancer (NSCLC). Mobosetinib, the first effective oral irreversible TKI designed to selectively target in-frame epidermal growth factor 20 protein mutations in non-small cell lung cancer, has been approved in multiple countries for use in patients with locally advanced or metastatic epidermal growth factor 20 protein mutant non-small cell lung cancer whose disease has progressed on prior platinum-based chemotherapy. Regarding the manufacturer of this drug, there are currently multiple versions on the market.

The original manufacturer of mobosetinib is the Japanese pharmaceutical company Takeda Pharmaceutical Company Limited (Takeda Pharmaceutical Company Limited). As one of the world's leading pharmaceutical companies, Takeda has rich R&D experience and innovative achievements in the field of cancer treatment. Mobosetinib developed by Takeda is mainly used to treat advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, and its trade name is Exkivity. The drug received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2021 and was approved for marketing in China on January 11, 2023.

In addition to Takeda Pharmaceuticals, several other manufacturers also produce generic versions of mobosetinib, aiming to meet market demand and the diversity of patient treatments. For example, Lucius Pharmaceuticals in Laos and Ziska Pharmaceuticals in Bangladesh also produce mobosetinib. Its pharmaceutical ingredients are similar to domestic and foreign original drugs. These different versions of the drug may have differences in price, packaging specifications, and marketing status in some countries.

Because moboxetinib is a prescription drug and involves cancer treatment, its production and sale are subject to strict regulations. When purchasing and using it, patients should be sure to choose formal channels and follow the doctor's advice and guidance.